Related Experiment Videos
Glycylcyclines: third-generation tetracycline antibiotics
1Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, UK. i.chopra@leeds.ac.uk
Current Opinion in Pharmacology
|January 5, 2002
Summary
Glycylcyclines offer a new approach to combatting microbial resistance to tetracycline antibiotics. Researchers are evaluating the effectiveness and potential for resistance to this new class of drugs.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Tetracycline antibiotics are crucial in human and veterinary medicine but face significant limitations due to widespread microbial resistance.
- The emergence of resistance has reduced the efficacy of traditional tetracyclines, necessitating the development of alternative antimicrobial agents.
Purpose of the Study:
- To introduce and discuss the development of glycylcyclines as a novel class of tetracycline antibiotics designed to overcome existing resistance mechanisms.
- To review recent microbiological, pharmacodynamic, and pharmacokinetic data for glycylcyclines, including the specific compound GAR-936 (tigilcycline).
Main Methods:
- Review of existing scientific literature and clinical trial data.
- Analysis of microbiological, pharmacodynamic, and pharmacokinetic properties of glycylcycline antibiotics.
Main Results:
- Glycylcyclines, such as GAR-936 (tigilcycline), are a new generation of tetracyclines developed to combat microbial resistance.
- Early data suggest potential efficacy, but ongoing research is necessary to fully characterize their properties.
Conclusions:
- Glycylcyclines represent a promising strategy to address the challenge of tetracycline resistance in medicine.
- Further investigation is required to understand the long-term efficacy and the potential for future resistance development to glycylcyclines.
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
7.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K
01:06Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
01:17Oral Hypoglycemic Agents: Sulfonylureas
718
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
718
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K